Heat Biologics, Inc. (NASDAQ: HTBX) is leading the immuno-oncology revolution. A clinical-stage company, Heat Biologics focuses on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell-based immunotherapy to treat patients with a wide array of cancers and infectious diseases. Heat Biologics’ ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient’s own immune system in order to destroy the cancer cells. For more information, visit the company’s website at www.heatbio.com.